| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Black hellebore is a perennial herb with a shallow rhizome blossoming during winter. Most often used with mistletoe. Helleborus niger extracts – Christmas Rose — Helleborus niger L. extracts are botanical preparations derived from the Christmas rose or black hellebore, a Ranunculaceae perennial native to parts of Europe. They are complex phytopharmaceutical mixtures rather than a single defined drug and may contain protoanemonin/ranunculin derivatives, steroidal saponins, ecdysteroids, phenolics, and, depending on plant part and preparation, bufadienolide cardiac glycosides such as hellebrin and hellebrigenin. HNE is commonly used as an abbreviation for Helleborus niger extract. Fresh-plant and fermented aqueous preparations have been used in anthroposophic and integrative medicine, including subcutaneous formulations, but H. niger extract is not an established anticancer drug and should not be equated with isolated hellebrin or hellebrigenin. Primary mechanisms (ranked):
Bioavailability / PK relevance: Formal human pharmacokinetic data for standardized Helleborus niger anticancer extracts are essentially absent. Extract composition varies substantially according to plant material and processing, and systemic exposures to individual active constituents after oral or subcutaneous administration are not well characterized. This makes translation from extract concentrations used experimentally to human tissue exposure uncertain. Bufadienolides additionally raise a potential narrow-therapeutic-index concern because Na⁺/K⁺-ATPase inhibition can affect cardiac electrophysiology. In-vitro vs systemic exposure relevance: Most direct anticancer evidence is concentration-driven in vitro. Some experiments with aqueous fermented HNE used approximately 600–1000 µg/mL to produce strong inhibition of tumor-cell migration, concentrations for which equivalent sustained systemic exposure in humans has not been demonstrated. Consequently, whole-extract in-vitro effects should not be interpreted as evidence that comparable antitumor concentrations are achievable clinically. Clinical evidence status: Preclinical. Helleborus niger extracts have demonstrated cytotoxic, pro-apoptotic, antiproliferative, antimigratory, and antiangiogenic activity in laboratory models. Clinical use exists mainly within complementary or anthroposophic medicine, and isolated case reports describe use alongside other therapies, but controlled human oncology trials demonstrating objective anticancer efficacy are lacking. It should therefore be classified as experimental adjunct use rather than an evidence-based cancer treatment. Helleborus niger Cancer-Relevant Mechanisms
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Drug dosage vs efficacy, and actual dosage number of research papers. |
| 7343- | Hne, | Comparative Evaluation of the Potential Antitumor of Helleborus purpurascens in Skin and Breast Cancer |
| - | in-vitro, | Melanoma, | A431 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | HaCaT | - | in-vitro, | Nor, | JB6 |
| 7342- | MT/VAE, | Hne, | Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts—a case report |
| - | Case Report, | MM, | NA |
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:93 Target#:1114 State#:% Dir#:4
wNotes=0 sortOrder:rid,rpid